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The hematopoietic disturbances related to cancer include erythrocytosis, cancer related anemia, and either thrombocytosis or thrombocytopenia.
Pancytopenia with erythroblastosis in peripheral blood is usually the consequence of bone marrow invasion and might be a terminal phenomenon. Treatment is supportive and includes transfusions of packed red blood cells, eventually platelets when needed. It is sometimes associated with disseminated intravascular coagulation when appropriate measures are required. Nevertheless this syndrome is usually a sign of generalized malignancy, not any more candidates for cytotoxic treatment.
Erithrocytosis has been traditionally associated with erythropoietin producing tumors such as renal cell carcinoma, hepatocelular carcinoma and cerebelar hemangioblastoma. In the clinical practice this syndrome is extremely rare. Erytrocytosis secondary to tumors is usually not high enough to require treatment.
Thrombocytosis is quite common in cancer patients and is usually associated with advanced disease. Thrombosis and hemorrhage are rarely associated with cancer thrombocytosis and if not associated with hypercoagulability syndrome does not require treatment. Anemia in cancer patients most commonly affects the form of the normocytic and normochromic anemia of chronic disease. It is supposedly caused by a number of factors including iron metabolism and storage disturbance and deficient erythropoietin production.
Recombinant erythropoietin has been avocated in low-grade cancer anemia but the issue remains controversial.
The most important hematological disturbances in cancer patients are migrating thrombophlebitis and disseminated intravascular coagulation. -As a terminal event in disseminated malignant disease; in this situation the specific treatment is usually ineffective and very often only symptomatic treatment is required.
-As a component of the tumor lysis syndrome; in this situation we are dealing with a chemotherapy responsive tumor and every effort of treatment with antithrombin III preparations, platelets transfusions and low molecular weight heparins is required.
-As a potentially transitory event during febrile neutropenia caused by gram-negative bacteria; this potentially fatal complication should be dealt with most seriously in order to save the patient. Treatment includes all measures as in the disseminated intravascular coagulation related to tumor lysis syndrome.
The synthesis of recombinant hematopoietic growth factors has opened a new era in treating cytopenic complications of both malignancy and chemotherapy. The recombinant factors that induce granulocytopoiesis i.e., GC-SF and GM-CSF have been synthesized and subject to extensive studies. ESMO has provided (11) minimal clinical recommendations for the applications of these factors outside controlled clinical trials.
It that been stated that rates of febrile neutropenia and related mortality rates are relatively low for most standard chemotherapies. These low rates do not justify routine use of G-CSF or GM-CSF in primary prevention of febrile neutropenia in routine chemotherapy regimens.
Indications for primary prophylaxis of febrile neutropenia include the probability of febrile neutropenia over 40% for a given chemotherapy regimen or situations where dose reduction is deemed to be detrimental to outcome.
The special situations for use of G-CSF or GM-CSF during chemotherapy include special situations for primary prophylaxis, secondary prophylaxis, and therapy of high-risk febrile neutropenia.
Primary prophylaxis is indicated when bone marrow reserve is a reduced due to:
-Prior extensive chemotherapy resulting in a stable neutrophil count below 1.5x109/L. -Need for chemotherapy dose reduction below threshold of efficacy.
-Need for delay of next treatment cycles if considered detrimental for response achievement and/or compromising cure rate or disease free and overall survival.
The granulocyte colonies promoting factors are indicated in the treatment of febrile neutropenia only in the category of high-risk febrile neutropenia i.e. febrile neutropenia lasting for more than 7 days, or associated with hypotension or sepsis, or associated with pneumonia or fungal infection.
The application of these factors is not indicated in the general therapy of febrile neutropenia and even less in the therapy of afebrile neutropenia. Their use is contraindicated during radiotherapy to the chest due to increased rate of complications and death. If they are given immediately prior or simultaneously with chemotherapy there is a risk for severe thrombocytopenia. They should not be applied in patients with chemotherapy induced bone marrow aplasia and severe thrombocytopenia. The use of hematopoietic growth factors in autologous or allogenic stem cell transplantation or for mobilization of peripheral blood stem cells is outside the scope of this presentation.
